Sanofi Stock Rises on Expanded $8 Billion Antibody Deal with Regeneron

Sanofi shares gained after the French drugmaker announced a significant expansion of its collaboration with Regeneron Pharmaceuticals, a deal potentially worth up to $8 billion to develop a new generation of antibody treatments for inflammatory diseases.

On the news, Sanofi stock (SASY) rose +1.4% to trade at €73.65. The rally comes as a welcome development for a stock that has been trading near multi-year lows and remains roughly 19% below its 52-week high of €91.15.

Details of the Expanded Alliance

Under the terms of the agreement, Sanofi will make an upfront payment of $1 billion to Regeneron. An additional $7 billion could be paid based on the achievement of specific development, regulatory, and commercial milestones.

The partnership will focus on co-developing and co-commercializing four new long-acting antibodies targeting inflammatory pathways. The companies will split all development costs and future profits equally. The four antibodies include one currently in a Phase 1 clinical trial for atopic dermatitis, REGN20423, and three others targeting key immune pathways.

Critically for investors, Sanofi confirmed that the existing profit-sharing arrangement for its blockbuster drug Dupixent, also developed with Regeneron, remains unaffected by this new deal.

Ad

Addressing Pipeline Concerns

The expanded collaboration is seen by the market as a strategic move to address a key investor concern: Sanofi's long-term growth prospects beyond the highly successful Dupixent franchise. This deal signals a clear strategy to build out its next wave of immunology treatments.

Regeneron’s chief scientific officer, George Yancopoulos, stated that the companies hope "to once again deliver the next wave of innovation in immunology." The agreement leverages Regeneron's discovery capabilities with Sanofi's global commercial infrastructure.

For investors, the deal's structure is also a positive. The milestone-contingent payments limit near-term financial dilution while providing significant upside potential, bolstering the case for a recovery in the company's valuation. Analyst consensus prior to the announcement held a 'Buy' rating with an average 12-month price target of €94.06, implying substantial upside from current levels.